** Shares of drugmaker United Therapeutics UTHR.O down 3.5% at $345 premarket
** Co posts quarterly adj profit of $6.19 per share, missing analysts' estimates of $6.31 per share, according to data compiled by LSEG
** However, co's Q4 revenue came in at $735.9 million on sales of its lung disorder inhaled-drug Tyvaso, slightly above estimates of $734.7 million
** Brokerage Leerink Partners says it appears that Tyvaso was not quite able to buck seasonal trends this quarter unlike a year ago
** The stock has risen ~60% in the last 12 months
(Reporting by Siddhi Mahatole)
((Siddhiprabhanjan.mahatole@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.